0RA9 Stock Chart & Stats
€108.40
€0.00(0.00%)
At close: 4:00 PM EDT
€108.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€60.70 - €139.00
Previous CloseN/A
Volume1.88K
Average Volume (3M)6.26K
Market Cap
€6.99B
Enterprise Value€8.80B
Total Cash (Recent Filing)€410.68M
Total Debt (Recent Filing)€1.21M
Price to Earnings (P/E)―
Beta3.27
Next Earnings
Dec 14, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.71
Shares Outstanding87,548,100
10 Day Avg. Volume2,169
30 Day Avg. Volume6,265
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€131.00Price Target Upside20.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.67
Revenue Forecast (FY)€4.21M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLow leverage and sharply higher equity in 2025 improve the company’s financial flexibility and near-term capacity to fund operations. This is a meaningful buffer for a clinical-stage business, although it does not replace the need to achieve internally generated profitability.
Strong Historical Gross MarginWhen revenue was recorded in 2022–2024, gross margin was near 100%, indicating strong gross economics in the revenue then recognized. If commercial revenue returns, that margin profile could support attractive contribution economics relative to sales.
Focused Therapeutic PipelineA focused pipeline aimed at chronic inflammatory diseases gives Abivax a defined therapeutic strategy rather than a broad, unfocused portfolio. Its lead program, obefazimod, is being investigated in ulcerative colitis and related indications, creating clear development focus.
Bears Say
Persistent Large LossesLarge, widening net and operating losses show that the current cost base is not supported by revenue generation. Continued unprofitability can consume financing capacity, reduce strategic flexibility, and make the company increasingly dependent on successful development and future commercialization.
Persistent Cash BurnPersistent negative operating and free cash flow means Abivax is not self-funding its research and operations. The roughly -162M free cash flow reported for 2025 indicates substantial ongoing cash needs, increasing dependence on external financing to sustain the business.
Unstable Revenue BaseRevenue volatility and the fall to zero in 2025 leave little evidence of a durable commercial revenue base. Without recurring revenue to offset its cost structure, Abivax remains reliant on external funding while clinical programs progress toward potential commercialization.
Abivax SA News
0RA9 FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest share price was €60.70 and its highest was €139.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €6.99B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Dec 14, 2026 which is in 46 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Sep 21, 2026. The company reported -€1.47 earnings per share for the quarter, missing the consensus estimate of -€0.801 by -€0.669.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.81.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,548,100 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.47 in its last earnings report, missing expectations of -€0.801. Following the earnings report the stock price went down -4.633%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in GB:0RA9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
0RA9 Stock 12 Month Forecast
Average Price Target
€131.00
▲(20.85% Upside)